UGT1A9 Genotyped Microsomes

Current Promotions

UDP-glucuronosyltransferases (UGTs) catalyze a wide variety of structurally dissimilar substrates, including drugs, endogenous molecules and carcinogens by glucuronidation; UGT1A9 is abundant in the human liver and is known for its reaction to phenols, steroids, organic acids, anticancer drugs and the procarcinogens in tobacco (Girard et al., 2004). UGT1A9 is most frequently studied for its interaction with the active metabolite of irinotecan and with the potentially specific probe propofol (Court 2005). UGT1A9*2 causes nucleotide change 8 (G>A) and amino acid change C3Y; UGT1A9*3 causes nucelotide change 98 (T>C) and amino acid change M33T. Villeneuve et al. (2003) showed that in HEK-293 cells, UGT1A9*3 dramatically impaired the conjugation of the cancer drug SN-38 (3.8% of wild type), but not flavopiridol-G, an obvious substrate-dependent impact; neither drug's conjugation was impaired by UGT1A9*2. Compared to the wild type UGT1A9*1, UGT1A9*3 is a low glucuronidating allele (Villeneuve et al., 2003).

UGT1A9 Allele Frequency
 
Allele African
American
Caucasian
UGT1A9*1 0.975 0.964-0.978
UGT1A9*2 0.025 -
UGT1A9*3 - 0.006-0.036

  Buy cell and tissue based products
Product Description Volume
HU1A9.HA Individual human liver microsomes, Genotyped for UGT1A9, high activity, 20mg/mL 0.5mL
HU1A9.MA Individual human liver microsomes, Genotyped for UGT1A9, moderate activity, 20mg/mL 0.5mL
HU1A9.NA Individual human liver microsomes, Genotyped for UGT1A9, no activity, 20mg/mL 0.5mL
*All genotyped human liver microsomes are supplied at a protein concentration of 20 mg/mL in 250 mM sucrose
  Find the Cellular Products You Need  
Can't find what you need? Have a question?
Or Call 1-877-588-7530
(+1.913.438.7450 If Outside North America)

 
Contact Us

Contact Us

Questions or inquiries? Use our contact form and we’ll reply as soon as possible.* indicates required field

Request A Quote
Request A Quote

Request A Quote

 Security code